Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes

Journal of Gastroenterology and Hepatology (Australia)

Volumn 33, Issue 1, 2018, Pages 270-276

  Sviklāne, Laura ^a,b   Olmane, Evija ^b,c   Dzērve, Zane ^a   Kupčs, Kārlis ^b,c   Pīrāgs, Valdis ^a,b   Sokolovska, Jeļizaveta ^a,b  

^a UNIVERSITY OF LATVIA   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c Magnetic Resonance Center DiaMed   (Latvia)

Author keywords

fatty liver index; hepatic steatosis index; metabolic syndrome; non alcoholic fatty liver disease; type 1 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE URINE LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; FATTY LIVER INDEX; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATIC STEATOSIS INDEX; HEPATOBILIARY PARAMETERS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PILOT STUDY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD STORAGE; COMPLICATION; DIAGNOSTIC IMAGING; ENZYMOLOGY; FATTY LIVER; LIVER; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; RISK; SEVERITY OF ILLNESS INDEX;

ADULT; BIOMARKERS; BLOOD PRESERVATION; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; FATTY LIVER; FEMALE; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; RISK; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 85039437574     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13814     Document Type: Article

References (31)

1. Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia 2016; 59: 1104–1111.
2. Kim D, Kim WR. Nonobese fatty liver disease. Clin. Gastroenterol. Hepatol. 2016 pii:S1542-3565(16)30608-5.
3. Argo CK, Henry ZH. Editorial: “Lean” NAFLD: metabolic obesity with normal BMI …. Is it in the genes? Am. J. Gastroenterol. 2017; 112: 111–113.
4. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 2015 Mar; 47: 181–190.
5. Chillarón JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism 2014; 63: 181–187.
6. Targher G, Bertolini L, Padovani R et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J. Hepatol. 2010; 53: 713–718.
7. Mantovani A, Mingolla L, Rigolon R et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int. J. Cardiol. 2016; 225: 387–391.
8. Targher G, Mantovani A, Pichiri I et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014; 37: 1729–1736.
9. Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Mohan V. Clinical profile of nonalcoholic fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India. Endocr. Pract. 2014; 20: 1249–1257.
10. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J. Gastroenterol. 2014; 20: 7392–7402.
11. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J. Hepatol. 2016; 65: 1006–1016.
12. Lee JH, Kim D, Kim HJ et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010; 42: 503–508.
13. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33.
14. Kahl S, Straßburger K, Nowotny B, Livingstone R, Klüppelholz B, Keßel K. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014; 9 e94059.
15. Fedchuk L, Nascimbeni F, Pais R et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2014; 40: 1209–1222.
16. 1H-MR spectroscopy. Eur. Radiol. 2012; 22: 855–863.
17. Silaghi CA, Silaghi H, Colosi HA et al. Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. Clujul Med 2016; 89: 82–88.
18. 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur. J. Endocrinol. 2014; 171: 561–569.
19. Stockwell T, Beirness D, Butt P, Gliksman L, Paradis C. Canada's low-risk drinking guidelines. CMAJ 2012; 184: 75.
20. Waden J et al. Leisure time physical activity is associated with poor glycemic control in type 1 diabetic women. Diabetes Care 2005; 28: 777–781.
21. Williams KV et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000; 49: 626–632.
22. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J. Magn. Reson. Imaging 2011; 34: 729–749.
23. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928–935.
24. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.
25. Xia MF, Yki-Järvinen H, Bian H et al. Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease. PLoS One 2016; 11 e0160526.
26. Bozkurt L, Göbl CS, Tura A et al. Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One 2012; 7 e32710.
27. Llauradó G, Sevastianova K, Sädevirta S et al. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2014; 100: 607–616.
28. Regnell SE, Lernmark Å. Hepatic steatosis in type 1 diabetes. Rev. Diabet. Stud. 2011; 8: 454–467.
29. Bulum T, Kolarić B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig. Dis. Sci. 2011; 56: 3655–3663.
30. 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep 2016; 6: 24031.
31. Sokolovska J, Isajevs S, Rostoka E et al. Changes in glucose transporter expression and nitric oxide production are associated with liver injury in diabetes. Cell Biochem. Funct. 2015; 33: 367–374.